14.27 USD
+0.03 (+0.21%)
14.2501 USD
-0.02 (-0.14%)
FOLD gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. Both the profitability and the financial health of FOLD get a neutral evaluation. Nothing too spectacular is happening here. FOLD has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
FOLD had negative earnings in the past year.
In the past year FOLD had a positive cash flow from operations.
In the past 5 years FOLD always reported negative net income.
In the past 5 years FOLD always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -1.62%, FOLD belongs to the top of the industry, outperforming 87.92% of the companies in the same industry.
With an excellent Return On Equity value of -6.10%, FOLD belongs to the best of the industry, outperforming 89.06% of the companies in the same industry.
FOLD has a Return On Invested Capital of 4.07%. This is amongst the best in the industry. FOLD outperforms 90.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.62% | ||
| ROE | -6.1% | ||
| ROIC | 4.07% |
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Operating Margin, with a value of 5.77%, FOLD belongs to the top of the industry, outperforming 89.81% of the companies in the same industry.
FOLD has a Gross Margin of 89.77%. This is amongst the best in the industry. FOLD outperforms 92.08% of its industry peers.
In the last couple of years the Gross Margin of FOLD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.77% | ||
| PM (TTM) | N/A | ||
| GM | 89.77% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so FOLD is destroying value.
The number of shares outstanding for FOLD has been increased compared to 1 year ago.
Compared to 5 years ago, FOLD has more shares outstanding
Compared to 1 year ago, FOLD has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.04, we must say that FOLD is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of FOLD (1.04) is better than 62.83% of its industry peers.
The Debt to FCF ratio of FOLD is 40.45, which is on the high side as it means it would take FOLD, 40.45 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 40.45, FOLD belongs to the top of the industry, outperforming 89.81% of the companies in the same industry.
A Debt/Equity ratio of 1.70 is on the high side and indicates that FOLD has dependencies on debt financing.
With a Debt to Equity ratio value of 1.70, FOLD is not doing good in the industry: 77.17% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.7 | ||
| Debt/FCF | 40.45 | ||
| Altman-Z | 1.04 |
ROIC/WACC0.44
WACC9.2%
2.3 Liquidity
A Current Ratio of 2.99 indicates that FOLD has no problem at all paying its short term obligations.
With a Current ratio value of 2.99, FOLD is not doing good in the industry: 64.15% of the companies in the same industry are doing better.
FOLD has a Quick Ratio of 2.09. This indicates that FOLD is financially healthy and has no problem in meeting its short term obligations.
FOLD's Quick ratio of 2.09 is on the low side compared to the rest of the industry. FOLD is outperformed by 72.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.99 | ||
| Quick Ratio | 2.09 |
3. Growth
3.1 Past
FOLD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 91.18%, which is quite impressive.
The Revenue has grown by 21.28% in the past year. This is a very strong growth!
The Revenue has been growing by 23.73% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)91.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%400%
Revenue 1Y (TTM)21.28%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%19.46%
3.2 Future
Based on estimates for the next years, FOLD will show a very strong growth in Earnings Per Share. The EPS will grow by 69.00% on average per year.
The Revenue is expected to grow by 19.14% on average over the next years. This is quite good.
EPS Next Y89.48%
EPS Next 2Y93.03%
EPS Next 3Y74.75%
EPS Next 5Y69%
Revenue Next Year19.4%
Revenue Next 2Y18.91%
Revenue Next 3Y18.81%
Revenue Next 5Y19.14%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for FOLD. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 45.93, FOLD can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, FOLD is valued cheaper than 91.13% of the companies in the same industry.
FOLD is valuated expensively when we compare the Price/Forward Earnings ratio to 23.23, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 45.93 |
4.2 Price Multiples
89.43% of the companies in the same industry are more expensive than FOLD, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of FOLD indicates a rather cheap valuation: FOLD is cheaper than 90.19% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 454.31 | ||
| EV/EBITDA | 105.83 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as FOLD's earnings are expected to grow with 74.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y93.03%
EPS Next 3Y74.75%
5. Dividend
5.1 Amount
FOLD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
14.27
+0.03 (+0.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners101.15%
Inst Owner Change0%
Ins Owners0.55%
Ins Owner Change-5.53%
Market Cap4.40B
Revenue(TTM)598.70M
Net Income(TTM)-14.06M
Analysts84.71
Price Target16.26 (13.95%)
Short Float %6.57%
Short Ratio2.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.12%
Min EPS beat(2)41.73%
Max EPS beat(2)52.51%
EPS beat(4)3
Avg EPS beat(4)76.91%
Min EPS beat(4)-26.06%
Max EPS beat(4)239.47%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.57%
Min Revenue beat(2)0.02%
Max Revenue beat(2)3.12%
Revenue beat(4)2
Avg Revenue beat(4)-1.83%
Min Revenue beat(4)-9.62%
Max Revenue beat(4)3.12%
Revenue beat(8)4
Avg Revenue beat(8)-0.79%
Revenue beat(12)8
Avg Revenue beat(12)-0.1%
Revenue beat(16)9
Avg Revenue beat(16)-1.08%
PT rev (1m)-0.39%
PT rev (3m)0.24%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.44%
EPS NY rev (1m)0%
EPS NY rev (3m)62.02%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)-0.84%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 45.93 | ||
| P/S | 7.35 | ||
| P/FCF | 454.31 | ||
| P/OCF | 339.3 | ||
| P/B | 19.11 | ||
| P/tB | 246.18 | ||
| EV/EBITDA | 105.83 |
EPS(TTM)-0.03
EYN/A
EPS(NY)0.31
Fwd EY2.18%
FCF(TTM)0.03
FCFY0.22%
OCF(TTM)0.04
OCFY0.29%
SpS1.94
BVpS0.75
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.62% | ||
| ROE | -6.1% | ||
| ROCE | 5.15% | ||
| ROIC | 4.07% | ||
| ROICexc | 6.72% | ||
| ROICexgc | 14.09% | ||
| OM | 5.77% | ||
| PM (TTM) | N/A | ||
| GM | 89.77% | ||
| FCFM | 1.62% |
ROA(3y)-19.77%
ROA(5y)-23.64%
ROE(3y)-105.3%
ROE(5y)-98.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.48%
GM growth 5Y0.45%
F-Score5
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.7 | ||
| Debt/FCF | 40.45 | ||
| Debt/EBITDA | 9.31 | ||
| Cap/Depr | 43.2% | ||
| Cap/Sales | 0.55% | ||
| Interest Coverage | 0.78 | ||
| Cash Conversion | 30.81% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.99 | ||
| Quick Ratio | 2.09 | ||
| Altman-Z | 1.04 |
F-Score5
WACC9.2%
ROIC/WACC0.44
Cap/Depr(3y)68.89%
Cap/Depr(5y)61.13%
Cap/Sales(3y)1.23%
Cap/Sales(5y)1.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)91.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%400%
EPS Next Y89.48%
EPS Next 2Y93.03%
EPS Next 3Y74.75%
EPS Next 5Y69%
Revenue 1Y (TTM)21.28%
Revenue growth 3Y20.03%
Revenue growth 5Y23.73%
Sales Q2Q%19.46%
Revenue Next Year19.4%
Revenue Next 2Y18.91%
Revenue Next 3Y18.81%
Revenue Next 5Y19.14%
EBIT growth 1Y139.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year23.46%
EBIT Next 3Y89.53%
EBIT Next 5YN/A
FCF growth 1Y105.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y108.46%
OCF growth 3YN/A
OCF growth 5YN/A
AMICUS THERAPEUTICS INC / FOLD FAQ
What is the fundamental rating for FOLD stock?
ChartMill assigns a fundamental rating of 4 / 10 to FOLD.
What is the valuation status for FOLD stock?
ChartMill assigns a valuation rating of 5 / 10 to AMICUS THERAPEUTICS INC (FOLD). This can be considered as Fairly Valued.
Can you provide the profitability details for AMICUS THERAPEUTICS INC?
AMICUS THERAPEUTICS INC (FOLD) has a profitability rating of 4 / 10.
What is the expected EPS growth for AMICUS THERAPEUTICS INC (FOLD) stock?
The Earnings per Share (EPS) of AMICUS THERAPEUTICS INC (FOLD) is expected to grow by 89.48% in the next year.